Q2-osavuosiraportti
77 päivää sitten‧48 min
Tarjoustasot
First North Denmark
Määrä
Osto
2 825 470
Myynti
Määrä
633 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 218 | - | - | ||
| 20 500 | - | - | ||
| 70 000 | - | - | ||
| 200 000 | - | - | ||
| 241 543 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 802 391
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 802 391
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenI'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡
·4 t sittenAnother positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·1 t sitten · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
·19 t sittenso 15 million just went in one go; there are some who are loading up the same as Overleif.·2 t sitten15mill x 0,01 = 150.000 - "large lot" ? & largest downgrade EVER in Danish stock market history - getting a bit tired of your dramaturgy O-leif - wait until 2026 then we'll see what happens - of course there are some who sell so they can use their losses against gains in probably Nvidia or Bitcoin - but it seems to me like a good level to supplement - but that's how different we are. EEn investor less here on Nordnet since yesterday - no dramatic exit as I see it.
·20 t sittenAbout today's guidance update. When reading today's update from management, I would strongly recommend that one for a moment forgets all the expensive fine words and the beautiful sales pitch and instead studies the numbers very carefully. Unfortunately, Nordnet has forgotten to include headings, but the column on the right is previous guidance and the one on the left is what the guidance has now been adjusted to. As one can see, some of the figures, including contracted sales value and cash flow, have been downgraded by an insane 70-80%. These figures are an unadulterated catastrophe. "Resistance to change" is an expression everyone knows. It is incredibly difficult to get people to change habits and do things in a new way. It often takes much longer than one imagines. Thus, one should have an understanding of the challenges that the management of brain faces. But no matter how much understanding one has, this “resistance to change” can have very serious consequences for companies, including Brain+, that try to do business in this market. The belief in break even still lives. Fine. But management also previously believed in contracted sales of 3,6 mill and now it has been reduced to a low 0,7. And this is not the first downgrade and postponement we have seen, and from this one must conclude that there is a serious risk of further shifts. And if that happens, they will not reach break even before they run out of money, and then we are left with yet another devastating share issue with yet another huge dilution as a result. If people think it doesn't matter, then fine.·3 t sittenGpt-gymnast, you just keep painting your eternal rosy picture. What you're coming up with now is 100% the same as what you've come up with 1000 times before, namely, tomorrow, tomorrow, tomorrow it will be better. It won't. When I have doubted that they would reach break even mid 2026, you have every time become, angry, pissed off and furious and called me all sorts of things. And you have also several times presented what you claim is proof that they would reach that breakeven. The idiotic "proof" has most often been based on calculations using sales budgets etc. But in the company's 14-year long lifetime, they have not once delivered a sales budget that has held. All the time and always it has been pure fantasy and fantasy figures. If a c25 at this time comes with a downward adjustment of just 5-10%, it will almost certainly mean a blood-red day with a share price drop of at least 10-15%. Brain+ delivers a downward adjustment of an insane 70-80%. I would think that must be close to a Danmarksrekord in downward adjustment. And yet there are people here who babble about good news having arrived. Most studies show that private small investors most often lose money on stocks, and one can certainly understand that when reading that kind of madness. The consequence of the downward adjustment is, among other things, that Break even will not be reached by mid 2026, precisely as I have doubted many times. Now it has become, that NOW WE HOPE TO REACH IT IN 2026. So far, all of Brain's and your predictions have failed. You haven't even been close. Mine have been better. And now you get two new predictions from me that you can get terribly offended by. Brain will not reach break even in 2026. And, we will thus not avoid yet another destructive emission. But good heavens, there are also people here who think it doesn't matter that within the foreseeable future there will probably be close to 2 billion shares, as I mentioned just a good week ago, and which you again were about to faint over. But it is very likely to happen, and the dilution will be tremendously destructive. If one believes it doesn't matter, then one should just buy plenty now. If you do that, then I hope in return you find another place to cry when the "bill" comes.- ·21 t sitten🚀 Brain+ 2025 Guidance Update – Short, sharp and condensed 1) Strategic key points (in practice, the most important) Market penetration in the UK is successful – 11 care providers, 28 care homes, 90 trained facilitators. All 11 customers extend to 2026 → extremely strong product-market fit and customer stickiness. Ayla is now the de facto standard for digital CST in the UK – the only solution with NICE-recommendation. Decision-makers react positively: Alzheimer’s Society, NHS Clinical Entrepreneur Programme, Care England-membership. The model is proven: 7-week implementation cycle → then scalable expansion site-for-site. Strong pipeline → the problem is timing, not demand. 2) Why guidance falls — and why it DOES NOT weaken the case Guidance is reduced due to extended sales cycle in UK care homes, not due to weak demand. UK care homes take 6–12 months to approve new solutions. Nevertheless: 28 sites in 9 months = much faster than industry standard. 11/11 renew → retention 100%. The pipeline is "matured" → 2026 will be the first year of real scaling. This is exactly what is seen with market penetration for health-SaaS in the UK. 3) Guidance figures – condensed Updated (2025) Contracted sales: 0,7–0,8 mio. DKK Cash from sales: 0,6–0,7 mio. Revenue recognized: 0,2–0,3 mio. Net loss: –14 to –15 mio. Guidance is primarily timing, because revenues will only truly materialize in 2026-2027. 4) The most important sign that growth accelerates in 2026 All 11 customers are on: ✔ Annual contract ✔ Ready for expansion ✔ Have already implemented CST with Ayla ✔ Are reference customers (great value) → This means 2026 will get automatic growth from: 1. multi-site rollout at existing customers 2. new customers from a now mature pipeline 3. greater credibility (Care England, NHS program, Alzheimer’s Society) 5) What does this mean for valuation and future potential? This announcement confirms 3 strong things: 1. The direction → 100% intact Strategic positioning in the UK is better than ever. 2. The business model → validated All customers renew despite a slow start. That is extremely positive for a SaaS business. 3. Scaling → starts in 2026 Once you are inside a care-home-brand, they roll out at group level. The model is roughly: 1 pilot-site 8–20 sites, if effect and economics are good → And they are. 6) What it means for the stock / investment case In short: 2025 = foundation 2026 = scaling 2027–2030 = national rollout + more countries This is precisely the classic pattern for digital health, and the guidance change alters nothing regarding the most important value drivers. With Ayla as: NICE-recommended NHS-validated Cost-saving documented (ROI > x100 in NHS models) … Brain+ stands uncommonly strong.
·20 t sittenIt's simply such incredibly good news that I have to buy another portion. It will go "to the moon" once the market discovers this gem!·18 t sittenEverything is now ready for the first time ever and we are participating massively in the biggest scene ever. All, truly all data, both economically and treatment-wise, are incredibly high that it cannot be ignored.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
77 päivää sitten‧48 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡
- ·4 t sittenAnother positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·1 t sitten · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
- ·19 t sittenso 15 million just went in one go; there are some who are loading up the same as Overleif.·2 t sitten15mill x 0,01 = 150.000 - "large lot" ? & largest downgrade EVER in Danish stock market history - getting a bit tired of your dramaturgy O-leif - wait until 2026 then we'll see what happens - of course there are some who sell so they can use their losses against gains in probably Nvidia or Bitcoin - but it seems to me like a good level to supplement - but that's how different we are. EEn investor less here on Nordnet since yesterday - no dramatic exit as I see it.
- ·20 t sittenAbout today's guidance update. When reading today's update from management, I would strongly recommend that one for a moment forgets all the expensive fine words and the beautiful sales pitch and instead studies the numbers very carefully. Unfortunately, Nordnet has forgotten to include headings, but the column on the right is previous guidance and the one on the left is what the guidance has now been adjusted to. As one can see, some of the figures, including contracted sales value and cash flow, have been downgraded by an insane 70-80%. These figures are an unadulterated catastrophe. "Resistance to change" is an expression everyone knows. It is incredibly difficult to get people to change habits and do things in a new way. It often takes much longer than one imagines. Thus, one should have an understanding of the challenges that the management of brain faces. But no matter how much understanding one has, this “resistance to change” can have very serious consequences for companies, including Brain+, that try to do business in this market. The belief in break even still lives. Fine. But management also previously believed in contracted sales of 3,6 mill and now it has been reduced to a low 0,7. And this is not the first downgrade and postponement we have seen, and from this one must conclude that there is a serious risk of further shifts. And if that happens, they will not reach break even before they run out of money, and then we are left with yet another devastating share issue with yet another huge dilution as a result. If people think it doesn't matter, then fine.·3 t sittenGpt-gymnast, you just keep painting your eternal rosy picture. What you're coming up with now is 100% the same as what you've come up with 1000 times before, namely, tomorrow, tomorrow, tomorrow it will be better. It won't. When I have doubted that they would reach break even mid 2026, you have every time become, angry, pissed off and furious and called me all sorts of things. And you have also several times presented what you claim is proof that they would reach that breakeven. The idiotic "proof" has most often been based on calculations using sales budgets etc. But in the company's 14-year long lifetime, they have not once delivered a sales budget that has held. All the time and always it has been pure fantasy and fantasy figures. If a c25 at this time comes with a downward adjustment of just 5-10%, it will almost certainly mean a blood-red day with a share price drop of at least 10-15%. Brain+ delivers a downward adjustment of an insane 70-80%. I would think that must be close to a Danmarksrekord in downward adjustment. And yet there are people here who babble about good news having arrived. Most studies show that private small investors most often lose money on stocks, and one can certainly understand that when reading that kind of madness. The consequence of the downward adjustment is, among other things, that Break even will not be reached by mid 2026, precisely as I have doubted many times. Now it has become, that NOW WE HOPE TO REACH IT IN 2026. So far, all of Brain's and your predictions have failed. You haven't even been close. Mine have been better. And now you get two new predictions from me that you can get terribly offended by. Brain will not reach break even in 2026. And, we will thus not avoid yet another destructive emission. But good heavens, there are also people here who think it doesn't matter that within the foreseeable future there will probably be close to 2 billion shares, as I mentioned just a good week ago, and which you again were about to faint over. But it is very likely to happen, and the dilution will be tremendously destructive. If one believes it doesn't matter, then one should just buy plenty now. If you do that, then I hope in return you find another place to cry when the "bill" comes.
- ·21 t sitten🚀 Brain+ 2025 Guidance Update – Short, sharp and condensed 1) Strategic key points (in practice, the most important) Market penetration in the UK is successful – 11 care providers, 28 care homes, 90 trained facilitators. All 11 customers extend to 2026 → extremely strong product-market fit and customer stickiness. Ayla is now the de facto standard for digital CST in the UK – the only solution with NICE-recommendation. Decision-makers react positively: Alzheimer’s Society, NHS Clinical Entrepreneur Programme, Care England-membership. The model is proven: 7-week implementation cycle → then scalable expansion site-for-site. Strong pipeline → the problem is timing, not demand. 2) Why guidance falls — and why it DOES NOT weaken the case Guidance is reduced due to extended sales cycle in UK care homes, not due to weak demand. UK care homes take 6–12 months to approve new solutions. Nevertheless: 28 sites in 9 months = much faster than industry standard. 11/11 renew → retention 100%. The pipeline is "matured" → 2026 will be the first year of real scaling. This is exactly what is seen with market penetration for health-SaaS in the UK. 3) Guidance figures – condensed Updated (2025) Contracted sales: 0,7–0,8 mio. DKK Cash from sales: 0,6–0,7 mio. Revenue recognized: 0,2–0,3 mio. Net loss: –14 to –15 mio. Guidance is primarily timing, because revenues will only truly materialize in 2026-2027. 4) The most important sign that growth accelerates in 2026 All 11 customers are on: ✔ Annual contract ✔ Ready for expansion ✔ Have already implemented CST with Ayla ✔ Are reference customers (great value) → This means 2026 will get automatic growth from: 1. multi-site rollout at existing customers 2. new customers from a now mature pipeline 3. greater credibility (Care England, NHS program, Alzheimer’s Society) 5) What does this mean for valuation and future potential? This announcement confirms 3 strong things: 1. The direction → 100% intact Strategic positioning in the UK is better than ever. 2. The business model → validated All customers renew despite a slow start. That is extremely positive for a SaaS business. 3. Scaling → starts in 2026 Once you are inside a care-home-brand, they roll out at group level. The model is roughly: 1 pilot-site 8–20 sites, if effect and economics are good → And they are. 6) What it means for the stock / investment case In short: 2025 = foundation 2026 = scaling 2027–2030 = national rollout + more countries This is precisely the classic pattern for digital health, and the guidance change alters nothing regarding the most important value drivers. With Ayla as: NICE-recommended NHS-validated Cost-saving documented (ROI > x100 in NHS models) … Brain+ stands uncommonly strong.·20 t sittenIt's simply such incredibly good news that I have to buy another portion. It will go "to the moon" once the market discovers this gem!·18 t sittenEverything is now ready for the first time ever and we are participating massively in the biggest scene ever. All, truly all data, both economically and treatment-wise, are incredibly high that it cannot be ignored.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
2 825 470
Myynti
Määrä
633 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 218 | - | - | ||
| 20 500 | - | - | ||
| 70 000 | - | - | ||
| 200 000 | - | - | ||
| 241 543 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 802 391
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 802 391
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
77 päivää sitten‧48 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenI'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡
- ·4 t sittenAnother positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·1 t sitten · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
- ·19 t sittenso 15 million just went in one go; there are some who are loading up the same as Overleif.·2 t sitten15mill x 0,01 = 150.000 - "large lot" ? & largest downgrade EVER in Danish stock market history - getting a bit tired of your dramaturgy O-leif - wait until 2026 then we'll see what happens - of course there are some who sell so they can use their losses against gains in probably Nvidia or Bitcoin - but it seems to me like a good level to supplement - but that's how different we are. EEn investor less here on Nordnet since yesterday - no dramatic exit as I see it.
- ·20 t sittenAbout today's guidance update. When reading today's update from management, I would strongly recommend that one for a moment forgets all the expensive fine words and the beautiful sales pitch and instead studies the numbers very carefully. Unfortunately, Nordnet has forgotten to include headings, but the column on the right is previous guidance and the one on the left is what the guidance has now been adjusted to. As one can see, some of the figures, including contracted sales value and cash flow, have been downgraded by an insane 70-80%. These figures are an unadulterated catastrophe. "Resistance to change" is an expression everyone knows. It is incredibly difficult to get people to change habits and do things in a new way. It often takes much longer than one imagines. Thus, one should have an understanding of the challenges that the management of brain faces. But no matter how much understanding one has, this “resistance to change” can have very serious consequences for companies, including Brain+, that try to do business in this market. The belief in break even still lives. Fine. But management also previously believed in contracted sales of 3,6 mill and now it has been reduced to a low 0,7. And this is not the first downgrade and postponement we have seen, and from this one must conclude that there is a serious risk of further shifts. And if that happens, they will not reach break even before they run out of money, and then we are left with yet another devastating share issue with yet another huge dilution as a result. If people think it doesn't matter, then fine.·3 t sittenGpt-gymnast, you just keep painting your eternal rosy picture. What you're coming up with now is 100% the same as what you've come up with 1000 times before, namely, tomorrow, tomorrow, tomorrow it will be better. It won't. When I have doubted that they would reach break even mid 2026, you have every time become, angry, pissed off and furious and called me all sorts of things. And you have also several times presented what you claim is proof that they would reach that breakeven. The idiotic "proof" has most often been based on calculations using sales budgets etc. But in the company's 14-year long lifetime, they have not once delivered a sales budget that has held. All the time and always it has been pure fantasy and fantasy figures. If a c25 at this time comes with a downward adjustment of just 5-10%, it will almost certainly mean a blood-red day with a share price drop of at least 10-15%. Brain+ delivers a downward adjustment of an insane 70-80%. I would think that must be close to a Danmarksrekord in downward adjustment. And yet there are people here who babble about good news having arrived. Most studies show that private small investors most often lose money on stocks, and one can certainly understand that when reading that kind of madness. The consequence of the downward adjustment is, among other things, that Break even will not be reached by mid 2026, precisely as I have doubted many times. Now it has become, that NOW WE HOPE TO REACH IT IN 2026. So far, all of Brain's and your predictions have failed. You haven't even been close. Mine have been better. And now you get two new predictions from me that you can get terribly offended by. Brain will not reach break even in 2026. And, we will thus not avoid yet another destructive emission. But good heavens, there are also people here who think it doesn't matter that within the foreseeable future there will probably be close to 2 billion shares, as I mentioned just a good week ago, and which you again were about to faint over. But it is very likely to happen, and the dilution will be tremendously destructive. If one believes it doesn't matter, then one should just buy plenty now. If you do that, then I hope in return you find another place to cry when the "bill" comes.
- ·21 t sitten🚀 Brain+ 2025 Guidance Update – Short, sharp and condensed 1) Strategic key points (in practice, the most important) Market penetration in the UK is successful – 11 care providers, 28 care homes, 90 trained facilitators. All 11 customers extend to 2026 → extremely strong product-market fit and customer stickiness. Ayla is now the de facto standard for digital CST in the UK – the only solution with NICE-recommendation. Decision-makers react positively: Alzheimer’s Society, NHS Clinical Entrepreneur Programme, Care England-membership. The model is proven: 7-week implementation cycle → then scalable expansion site-for-site. Strong pipeline → the problem is timing, not demand. 2) Why guidance falls — and why it DOES NOT weaken the case Guidance is reduced due to extended sales cycle in UK care homes, not due to weak demand. UK care homes take 6–12 months to approve new solutions. Nevertheless: 28 sites in 9 months = much faster than industry standard. 11/11 renew → retention 100%. The pipeline is "matured" → 2026 will be the first year of real scaling. This is exactly what is seen with market penetration for health-SaaS in the UK. 3) Guidance figures – condensed Updated (2025) Contracted sales: 0,7–0,8 mio. DKK Cash from sales: 0,6–0,7 mio. Revenue recognized: 0,2–0,3 mio. Net loss: –14 to –15 mio. Guidance is primarily timing, because revenues will only truly materialize in 2026-2027. 4) The most important sign that growth accelerates in 2026 All 11 customers are on: ✔ Annual contract ✔ Ready for expansion ✔ Have already implemented CST with Ayla ✔ Are reference customers (great value) → This means 2026 will get automatic growth from: 1. multi-site rollout at existing customers 2. new customers from a now mature pipeline 3. greater credibility (Care England, NHS program, Alzheimer’s Society) 5) What does this mean for valuation and future potential? This announcement confirms 3 strong things: 1. The direction → 100% intact Strategic positioning in the UK is better than ever. 2. The business model → validated All customers renew despite a slow start. That is extremely positive for a SaaS business. 3. Scaling → starts in 2026 Once you are inside a care-home-brand, they roll out at group level. The model is roughly: 1 pilot-site 8–20 sites, if effect and economics are good → And they are. 6) What it means for the stock / investment case In short: 2025 = foundation 2026 = scaling 2027–2030 = national rollout + more countries This is precisely the classic pattern for digital health, and the guidance change alters nothing regarding the most important value drivers. With Ayla as: NICE-recommended NHS-validated Cost-saving documented (ROI > x100 in NHS models) … Brain+ stands uncommonly strong.·20 t sittenIt's simply such incredibly good news that I have to buy another portion. It will go "to the moon" once the market discovers this gem!·18 t sittenEverything is now ready for the first time ever and we are participating massively in the biggest scene ever. All, truly all data, both economically and treatment-wise, are incredibly high that it cannot be ignored.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
2 825 470
Myynti
Määrä
633 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 218 | - | - | ||
| 20 500 | - | - | ||
| 70 000 | - | - | ||
| 200 000 | - | - | ||
| 241 543 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 802 391
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 802 391
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 802 391 | 802 391 | 0 | 0 |